Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 November 2012Website:
http://www.travere.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 01 Jul 2024 22:56:42 GMTDividend
Analysts recommendations
Institutional Ownership
TVTX Latest News
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
While the financial results of Travere (TVTX) for the quarter ending in March 2024 provide an indication of the company's performance, it may be beneficial to examine how certain important metrics stack up against analyst predictions and previous year's figures.
Travere Therapeutics (TVTX) reported a quarterly loss of $1.76 per share, exceeding the Zacks Consensus Estimate of a loss of $0.98. This is higher than the loss of $1.27 per share reported in the same quarter last year.
Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Call Transcript
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET.
Travere (TVTX) is on track to file an sNDA to the FDA to convert the accelerated approval for lead drug, Filspari, to full approval for IgAN in first-quarter 2024.
Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs.
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the 6th Annual Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023, at 8:20 a.m. ET.
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2023 Results Conference Call November 7, 2023 4:30 PM ET Company Participants Naomi Eichenbaum - Vice President-Investor Relations Dr. Eric Dube - Chief Executive Officer Dr. Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer Dr. Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JP Morgan Maury Raycroft - Jefferies Greg Harrison - Bank of America Vamil Divan - Guggenheim Securities Liisa Bayko - Evercore.ISI Edwin Delfin - Barclays Laura Chico - Wedbush Securities Alex Thompson - Stifel Allison Bratzel - Piper Sandler Ed Arce - H.C. Wainwright & Company Operator Good day, and welcome to the Travere Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call.
- 1(current)
What type of business is Travere Therapeutics?
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
What sector is Travere Therapeutics in?
Travere Therapeutics is in the Healthcare sector
What industry is Travere Therapeutics in?
Travere Therapeutics is in the Biotechnology industry
What country is Travere Therapeutics from?
Travere Therapeutics is headquartered in United States
When did Travere Therapeutics go public?
Travere Therapeutics initial public offering (IPO) was on 08 November 2012
What is Travere Therapeutics website?
https://www.travere.com
Is Travere Therapeutics in the S&P 500?
No, Travere Therapeutics is not included in the S&P 500 index
Is Travere Therapeutics in the NASDAQ 100?
No, Travere Therapeutics is not included in the NASDAQ 100 index
Is Travere Therapeutics in the Dow Jones?
No, Travere Therapeutics is not included in the Dow Jones index
When does Travere Therapeutics report earnings?
The next expected earnings date for Travere Therapeutics is 02 August 2024